Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience

IntroductionReal-life experience with imipenem/cilastatin/relebactam (IMI/REL) for the treatment of KPC-producing Klebsiella pneumoniae complex (KPC-Kp) and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa (DTR-PA) infections is herein described.MethodsAdult patients with KPC-Kp or DTR-PA...

Full description

Bibliographic Details
Published in:	Frontiers in Microbiology
Main Authors:	Cristiana Leanza, Maria Teresa Mascellino, Lorenzo Volpicelli, Sara Covino, Antonio Falletta, Francesca Cancelli, Cristiana Franchi, Martina Carnevalini, Claudio M. Mastroianni, Alessandra Oliva
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-07-01
Subjects:	imipenem-relebactam KPC-producing Klebsiella pneumoniae imipenem/cilastatin/relebactam ceftazidime-avibactam resistance polymicrobial infections antimicrobial resistance
Online Access:	https://www.frontiersin.org/articles/10.3389/fmicb.2024.1432296/full

Similar Items

Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
by: Isabel Machuca, et al.
Published: (2024-11-01)

Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials
by: Wenjuan Lei, et al.
Published: (2025-09-01)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
by: Dai Kurihara, et al.
Published: (2022-04-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
by: Jaesh Naik, et al.
Published: (2023-01-01)

Activity of imipenem/relebactam against KPC-producing Klebsiella pneumoniae and the possible role of Ompk36 mutation in determining resistance: an Italian retrospective analysis
by: Emanuele Palomba, et al.
Published: (2025-04-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
by: Qingxin Yang, et al.
Published: (2023-12-01)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
by: Soo Min Jang, et al.
Published: (2021-09-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
by: Ryan K. Shields, et al.
Published: (2024-06-01)

Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam
by: Peiyao Jia, et al.
Published: (2025-09-01)

Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis
by: Reza Abniki, MS, et al.
Published: (2024-01-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
by: Pasquale Sansone, et al.
Published: (2024-05-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
by: Paul Laffont-Lozes, et al.
Published: (2024-10-01)

Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan
by: Tsung-Ying Yang, et al.
Published: (2022-02-01)

AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility
by: Shawn Freed, Jr, et al.
Published: (2024-11-01)

Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS
by: Ana Candela, et al.
Published: (2025-05-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

In vitro activity of imipenem/relebactam and comparators against Enterobacterales isolates collected in Brazilian hospitals according to results from the Study for Monitoring Antimicrobial Resistance Trends, 2020–2021
by: Amanda Azevedo Bittencourt, et al.
Published: (2025-07-01)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
by: Katherine Young, et al.
Published: (2019-07-01)

Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
by: Xueting Wang, et al.
Published: (2023-12-01)

In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates
by: Dan Li, et al.
Published: (2023-12-01)

Efficacy and safety of novel carbapenem–β-lactamase inhibitor combinations: Results from phase II and III trials
by: Wei Yu, et al.
Published: (2022-09-01)

Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR <i>Klebsiella pneumoniae</i> Sternal Infection Complicated by Bacteremia
by: Luca Pipitò, et al.
Published: (2025-10-01)

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
by: FATMA SENA TÜRKDOĞAN, et al.
Published: (2024-12-01)

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient
by: Paolo Gaibani, et al.
Published: (2022-04-01)

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)
by: Marta Hernández-García, et al.
Published: (2022-10-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
by: Hiroki Nakamura, et al.
Published: (2024-03-01)

In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of <i>Mycobacterium abscessus</i>
by: Madeline Sanders, et al.
Published: (2025-05-01)

In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of <i>Mycobacterium abscessus</i> Complex Isolates
by: Alejandro Seoane-Estévez, et al.
Published: (2025-07-01)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020
by: James A. Karlowsky, et al.
Published: (2023-05-01)

Mycobacterium abscessus skin and soft tissue infection following autologous fat grafting in Kurdistan treated with an antibiotic combination including Imipenem-Relebactam and Rifabutin
by: Alison J. Beech, et al.
Published: (2023-08-01)

In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer
by: Kenneth V.I. Rolston, et al.
Published: (2022-06-01)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
by: Xi You, et al.
Published: (2024-03-01)

Integrative greenness, blueness and whiteness determination of analytical RP-HPLC method for identifying Imipenem, Cilastatin and Relebactam in combined tablet form followed by forced degradation studies
by: Revathy Sundara Moorthy, et al.
Published: (2024-12-01)

<i>Klebsiella pneumoniae</i> Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio
by: Maria V. Golikova, et al.
Published: (2022-06-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
by: Telma de Sousa, et al.
Published: (2023-11-01)

Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs
by: Ilias Karaiskos, et al.
Published: (2025-05-01)

Restoring Control: Real-World Success with Imipenem–Relebactam in Critical MDR Infections—A Multicenter Observational Study
by: Andrea Marino, et al.
Published: (2025-07-01)

Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades
by: Daniele Roberto Giacobbe, et al.
Published: (2023-12-01)

Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018–2021
by: Yu-Lin Lee, et al.
Published: (2024-06-01)